CompletedPHASE1, PHASE2NCT03157804
Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A
Studying Fanconi anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
- Principal Investigator
- Juan A BuerenCIEMAT/CIBERER/IIS.FJD
- Intervention
- IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)(procedure)
- Enrollment
- 9 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2016 – 2023
Study locations (2)
- Hospital Vall d'Hebron, Barcelona, Spain
- Hospital Infantil del Niño Jesus, Madrid, Spain
Collaborators
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT) · Centro de Investigación en Red de Enfermedades Raras (CIBERER) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Hospital Vall d'Hebron · Universitat Autonoma de Barcelona
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03157804 on ClinicalTrials.govOther trials for Fanconi anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06744283Experience and Management of Cancer Screening-Related Anxiety in Fanconi AnemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06648096Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- RECRUITINGNANCT05687149Defining the Natural History of Squamous Cell Carcinoma in Fanconi AnemiaNational Cancer Institute (NCI)
- RECRUITINGNANCT05973656Role of Acetaldehyde in the Development of Oral CancerMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE1, PHASE2NCT04784052Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing BriquilimabPorteus, Matthew, MD
- ACTIVE NOT RECRUITINGPHASE2NCT04248439Gene Therapy for Fanconi Anemia, Complementation Group ARocket Pharmaceuticals Inc.
- ACTIVE NOT RECRUITINGNANCT04437771Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene TherapyRocket Pharmaceuticals Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04069533Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype ARocket Pharmaceuticals Inc.